Medical Oncologist
CION Cancer Clinics
Choosing between immunotherapy and tablets for advanced liver cancer | CION Cancer Clinics
For most people with advanced liver cancer and a liver that still works well, an immunotherapy combination is now the usual first treatment. Tablets such as sorafenib or lenvatinib are the right first choice for people who cannot safely have immunotherapy. This page explains what your team weighs, how the decision is made, and who each path does not suit. At CION Cancer Clinics, a multidisciplinary tumour board weighs your liver function and your scans before recommending any treatment.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed October 2026, next review due October 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- Should I have immunotherapy or tablets for liver cancer?
- What decides which treatment suits me?
- How is the decision actually made?
- How do immunotherapy and tablets compare?
- Who does immunotherapy not suit, and who do tablets not suit?
- What this page cannot tell you
- Common questions about immunotherapy or tablets
The short answer
Should I have immunotherapy or tablets for liver cancer?
For most people with advanced hepatocellular carcinoma (HCC, the cancer that starts in the liver itself) and reasonably good liver function, an immunotherapy combination is now the usual first choice. Tablets such as sorafenib or lenvatinib remain a sound first choice for people who cannot safely have immunotherapy.
Who this page is for
This page is for someone whose liver cancer cannot be removed, burned away or controlled with treatment into the liver's blood supply, so a medicine that works through the whole body becomes the main treatment. If your scan shows cancer that spread to the liver from the bowel, breast or elsewhere, the choices are different. Start with what secondary liver cancer means.
The two main paths
The immunotherapy path usually means atezolizumab plus bevacizumab, or durvalumab plus tremelimumab, given as a drip at the centre. The tablet path means sorafenib or lenvatinib, taken at home every day. Neither path is a weaker version of the other for the right person. The question is which one fits your liver, your body and your life.
The choice is made by your oncologist with you, after the tumour board has looked at your scans and blood results.What the team weighs
What decides which treatment suits me?
Four things matter more than anything else. The cancer itself is only one of them.
How well your liver works
Both paths were tested mainly in people whose liver still copes well, called Child-Pugh A. If the liver is struggling, with fluid in the belly, jaundice or confusion, every option carries more risk and the plan becomes more cautious.
Bleeding risk
Bevacizumab can make bleeding more likely. People with cirrhosis often have varices, swollen veins in the food pipe that can bleed. These are checked and treated first.
Your immune system
Immunotherapy releases a brake on the immune system. That is a problem for some people.
- A previous liver transplant
- An active autoimmune illness, such as lupus
- Hepatitis B that is not yet controlled
Daily life and access
A drip means regular visits to a day-care unit. Tablets mean daily side effects managed at home. Travel from the district, cost and scheme cover all shape what is realistic for your family.
Not sure whether this applies to you?
Ask an oncologistStep by step
How is the decision actually made?
The scans and reports are reviewed together
The multidisciplinary tumour board at CION looks at your scans and biopsy, if one was done, and confirms that a whole-body medicine is the right main treatment rather than surgery, ablation or TACE.
Your liver function is measured
Blood tests for bilirubin (the yellow pigment), albumin (a protein the liver makes) and clotting give a Child-Pugh score. This tells the team how much treatment your liver can take.
Hepatitis is checked and controlled
If you carry hepatitis B, antiviral tablets are started or adjusted with a hepatologist before treatment begins, so the virus does not flare.
An endoscopy looks for varices
Before bevacizumab, a camera test looks for swollen veins. CION arranges this through partner hospitals. Read why the endoscopy comes first.
You talk it through and choose
Your oncologist explains each option, its likely side effects and its cost. You and your family decide together, and the first review scan is planned.
Side by side
How do immunotherapy and tablets compare?
Immunotherapy combination
Sorafenib or lenvatinib tablets
Usually the first choice when the liver is working well
First choice when immunotherapy is not safe or not possible
Given as a drip at regular day-care visits
Taken by mouth at home every day
Side effects can be immune reactions in the skin, gut, liver or glands
Side effects are often sore hands and feet, diarrhoea, raised blood pressure and tiredness
Needs varices checked first if bevacizumab is used
Needs blood pressure and skin checked closely
Not used after a liver transplant
Can be used after a transplant, with care
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Not for everyone
Who does immunotherapy not suit, and who do tablets not suit?
Immunotherapy usually does not suit someone who has had a liver transplant, because it can make the body reject the new liver. Read why immunotherapy is avoided after a transplant. It needs great care in people with an active autoimmune illness, or with hepatitis B that is not yet under control. The immunotherapy with hepatitis B or cirrhosis page explains what changes.
When bevacizumab is the problem
People with large varices that have not been treated, a recent bleed, or a recent clot or stroke may not be able to have bevacizumab. For them, durvalumab plus tremelimumab, immunotherapy alone, or tablets may be discussed instead.
When tablets are the problem
Tablets can be hard for people with blood pressure that is difficult to control, a weak heart, or skin and gut problems that daily side effects would make worse. People who cannot be watched closely at home may also struggle.
When neither suits
If the liver is failing badly, with Child-Pugh C function, cancer medicine of either kind usually does more harm than good. Care then focuses on comfort and the liver itself.
Being straight with you
What this page cannot tell you
It cannot tell you which treatment is right for you. That depends on your scans, your blood results, your other illnesses and your own priorities, and only your oncologist can put those together. It also cannot tell you how long either treatment will work for you. Averages from trials say little about one person.
It cannot tell you what is available this month
Not every combination is easy to get in India at every point. Tremelimumab in particular has had limited availability, and supply and scheme cover change. Your oncologist will tell you what can actually be obtained when you start.
Where the detail lives
How each medicine works and how its side effects are handled is covered on our medicine pages. The tablet comparison is on lenvatinib versus sorafenib. This page covers only the choice between the two paths.
If you have been offered one path and want to know why not the other, ask. It is a fair question, and a second opinion is always reasonable.Questions we are asked
Common questions about immunotherapy or tablets
Is immunotherapy always better than tablets?
No. For most people with good liver function it is the usual first choice, because trials compared it directly with sorafenib. But for someone who cannot safely have it, tablets are the right first treatment. The better treatment is the one your body can take safely.
Can I switch to tablets if immunotherapy stops working?
Often, yes. When the first treatment stops controlling the cancer, and the liver is still coping, tablets such as lenvatinib or sorafenib are commonly used next. Your team will check your liver function and fitness again before suggesting the next step.
Do the tablets work if I tried immunotherapy first?
Tablets can still help after immunotherapy. The evidence for the exact order is thinner than for first treatment, because the older trials were done before immunotherapy was standard. Your oncologist will explain what is known and what is not.
Why do I need an endoscopy before immunotherapy?
The endoscopy is needed because of bevacizumab, which is often given with atezolizumab. It can make bleeding more likely, and people with cirrhosis may have swollen veins in the food pipe. Treating these first makes the drip safer.
I have hepatitis B. Can I still have immunotherapy?
Usually, yes, as long as the virus is controlled with antiviral tablets first. Hepatitis B is controlled rather than removed from the body, so those tablets are normally continued throughout. A hepatologist or physician manages the antiviral side.
Which is cheaper, the drip or the tablets?
It varies with the brand, generic or biosimilar versions, scheme cover and how long treatment lasts. Ask for a written, itemised estimate for each option you are offered. Our page on the monthly cost of each option explains what moves the bill.
Can these treatments make the cancer go away completely?
For advanced liver cancer the aim is control, not removal. The cancer may shrink or stop growing, sometimes for a long time. Very occasionally it shrinks enough for other treatments to be considered, but nobody can promise that at the start.
Where do I start if I want my plan reviewed?
Gather your scan reports, the scan images on a disc or link, your biopsy report and recent blood tests. Call the CION helpline, and a medical oncologist will review them with the tumour board and explain which path suits you and why.
Your Specialists
Meet CION's liver cancer specialists. Bring your scan reports and liver blood tests.
Our medical and surgical oncologists plan liver cancer care together, weighing the tumour and how well your liver works before choosing surgery, a liver-directed procedure or medicines.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- American Cancer Society — Immunotherapy for Liver Cancer
- American Cancer Society — Targeted Drug Therapy for Liver Cancer
- EASL — EASL Clinical Practice Guidelines: management of hepatocellular carcinoma
- Cancer Research UK — Treatment for liver cancer
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Atezolizumab plus bevacizumab for liver cancerThe usual first-choice combination, in detailWho cannot have atezolizumab plus bevacizumabCheck whether any of the exclusions apply to youSorafenib or lenvatinib: how the choice is madeIf tablets are your path, which oneThe monthly cost of each systemic optionWhat each path is likely to cost your family
Talk to us
Not sure why you were offered one path and not the other?
Send us your scans and blood reports and a medical oncologist will explain which option fits your liver and why. One helpline serves every CION centre.